Literature DB >> 29396328

Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.

Shinsuke Sasada1, Norio Masumoto2, Noriko Goda2, Keiko Kajitani2, Akiko Emi2, Takayuki Kadoya2, Morihito Okada2.   

Abstract

PURPOSE: Diagnostic methods to evaluate the response to neoadjuvant chemotherapy (NAC) for breast cancer have not been established. Dedicated breast PET (DbPET) is a high-resolution molecular breast imaging method, and we investigated the capability of DbPET to predict residual primary tumors after NAC compared with whole-body PET (WBPET).
METHODS: Forty-five patients (47 tumors) underwent WBPET and ring-type DbPET after NAC, and the tumors were completely resected between January 2016 and March 2017. The pathological response was classified as complete remission (ypT0), residual intraductal disease (ypTis), or residual invasive disease (ypT ≥ 1). Standardized uptake value (SUV) and tumor-to-normal tissue ratio (TNR) were assessed.
RESULTS: Twelve patients achieved ypT0 and five developed ypTis. DbPET detected all cases of ypTis, and WBPET detected only one case of ypTis. The sensitivity, specificity, and accuracy of WBPET for ypTis and/or ypT ≥ 1 were 54.3%, 83.3%, and 61.7%, respectively, and those of DbPET were 77.1%, 83.3%, and 78.7%, respectively. In the ypT0/ypTis/ypT ≥ 1 groups, the median WBPET-SUV, DbPET-SUV, and DbPET-TNR was 1.0/0.9/1.1, 1.7/1.8/2.2, and 1.0/1.6/1.7 (P = .134, .077, and 0.008), respectively. Areas under the curves of WBPET-SUV, DbPET-SUV, and DbPET-TNR for predicting ypTis and/or ypT ≥ 1 were 0.610, 0.648, and 0.807, respectively.
CONCLUSIONS: DbPET was more accurate than WBPET in detecting residual primary tumors after NAC, particularly intraductal carcinoma. TNR was the better parameter for pathological evaluation compared with SUV.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Breast cancer; Dedicated breast PET; FDG; Neoadjuvant chemotherapy; Response

Mesh:

Substances:

Year:  2018        PMID: 29396328     DOI: 10.1016/j.ejso.2018.01.014

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.

Authors:  Yukiko Tokuda; Masahiro Yanagawa; Yuka Fujita; Keiichiro Honma; Tomonori Tanei; Masafumi Shimoda; Tomohiro Miyake; Yasuto Naoi; Seung Jin Kim; Kenzo Shimazu; Seiki Hamada; Noriyuki Tomiyama
Journal:  Breast Cancer Res Treat       Date:  2021-03-17       Impact factor: 4.872

Review 2.  Innovative Standards in Surgery of the Breast after Neoadjuvant Systemic Therapy.

Authors:  Tal Hadar; Michael Koretz; Mahmood Nawass; Tanir M Allweis
Journal:  Breast Care (Basel)       Date:  2021-11-02       Impact factor: 2.860

3.  Diagnostic performance of dedicated breast positron emission tomography.

Authors:  Rikako Hashimoto; Sadako Akashi-Tanaka; Chie Watanabe; Hiroko Masuda; Kanae Taruno; Tomoko Takamaru; Yoshimi Ide; Takashi Kuwayama; Yasuhiro Kobayashi; Masafumi Takimoto; Seigo Nakamura
Journal:  Breast Cancer       Date:  2022-06-29       Impact factor: 3.307

4.  Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.

Authors:  Deep K Hathi; Wen Li; Youngho Seo; Robert R Flavell; John Kornak; Benjamin L Franc; Bonnie N Joe; Laura J Esserman; Nola M Hylton; Ella F Jones
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

5.  Malignant prediction of incidental findings using ring-type dedicated breast positron emission tomography.

Authors:  Shinsuke Sasada; Norio Masumoto; Akiko Emi; Takayuki Kadoya; Morihito Okada
Journal:  Sci Rep       Date:  2022-01-21       Impact factor: 4.379

Review 6.  Assessment and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Imaging Modalities and Future Perspectives.

Authors:  Valeria Romeo; Giuseppe Accardo; Teresa Perillo; Luca Basso; Nunzia Garbino; Emanuele Nicolai; Simone Maurea; Marco Salvatore
Journal:  Cancers (Basel)       Date:  2021-07-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.